Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis
- 8 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (8) , 824-829
Abstract
Objectives: PET using 18F-fluorodeoxyglucose (FDG) has proven to be valuable in staging and monitoring of treatment response in breast cancer. We aimed to assess the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with breast cancer. Methods: A systematic search of MEDLINE and EMBASE was performed using the keywords of breast cancer, PET, and volume. Inclusion criteria were 18F-FDG PET used as an initial imaging tool; studies limited to patients with breast cancer who had not undergone any treatment before PET scans; and studies reporting survival data. Event-free survival (EFS) and overall survival (OS) were considered markers of outcome. Results: Nine studies comprising 975 patients were included in this study. The pooled hazard ratio (HR) for adverse events was 33.73 (P < 0.00001; I2 = 0%) with MTV from primary tumor and 2.89 (P < 0.00001; I2 = 45%) with TLG from primary tumor, meaning that primary tumors with high volumetric parameters were associated with progression or recurrence. However, the combined HRs for EFS of MTV, and TLG, and those for OS of MTV from whole-body tumor were NS. The pooled HR for OS of TLG from whole-body tumor was 2.95 (P = 0.18; I2 = 71%). Conclusion: Volumetric parameters from 18F-FDG PET are significant prognostic factors for outcome in patients with breast cancer. Patients with a high MTV or TLG from primary tumor have a higher risk of adverse events. Patients with a high TLG from whole-body tumor have a higher risk of deaths.Keywords
This publication has 26 references indexed in Scilit:
- Whole-Body Metabolic Tumor Volume, as Determined by 18F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant MetastasisAmerican Journal of Roentgenology, 2015
- Risk stratification in patients with advanced‐stage breast cancer by pretreatment [18F]FDG PET/CTCancer, 2015
- Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burdenBreast Cancer Research, 2014
- Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the BreastNuclear Medicine and Molecular Imaging, 2014
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-AnalysisJournal of Nuclear Medicine, 2014
- Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography or PET-Computed Tomography in Cervical CancerInternational Journal of Gynecological Cancer, 2013
- Prognostic Significance of Volume-Based PET Parameters in Cancer PatientsKorean Journal of Radiology, 2013
- Preoperative PET/CT in early-stage breast cancerAnnals of Oncology, 2012
- Measuring inconsistency in meta-analysesBMJ, 2003